Diclofenac epolamine and Lumacaftor and ivacaftor
Determining the interaction of Diclofenac epolamine and Lumacaftor and ivacaftor and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor. The clinical relevance is unknown. MANAGEMENT: Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy. References "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA. "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. View all 4 references
Professional:MONITOR: Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of CYP450 2C9 by ivacaftor. The clinical relevance is unknown.
MANAGEMENT: Caution is advised when ivacaftor is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.
- "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
Generic Name: diclofenac
Brand name: Cambia, Cataflam, Voltaren-XR, Zipsor, Zorvolex, Voltaren, Dyloject, also Cambia
Synonyms: Diclofenac, Diclofenac (Systemic)
Generic Name: ivacaftor / lumacaftor
Brand name: Orkambi
Synonyms: Ivacaftor and lumacaftor, Lumacaftor and Ivacaftor
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Diclofenac epolamine-Lumacaftor and Ivacaftor Granules
- Diclofenac epolamine-Lumacaftor and Ivacaftor Tablets
- Diclofenac epolamine-Lumason
- Diclofenac epolamine-Lumify
- Diclofenac epolamine-Lumigan
- Diclofenac epolamine-Luminal
- Lumacaftor and ivacaftor-Diclofenac Epolamine Patch
- Lumacaftor and ivacaftor-Diclofenac Extended Release Tablets 100mg
- Lumacaftor and ivacaftor-Diclofenac Extended-Release Tablets
- Lumacaftor and ivacaftor-Diclofenac Gel
- Lumacaftor and ivacaftor-Diclofenac Gel (1%)
- Lumacaftor and ivacaftor-Diclofenac Gel (3%)